Wilson Disease, Two Presentations: Why the Same Diagnosis Doesn't Mean the Same First Drug
Two newly diagnosed Wilson disease patients need copper-reducing therapy in the same week. One presented with liver injury alone; the other with tremor and dysarthria. The diagnosis is identical. The first drug shouldn't be.
Simon L., a 22-year-old man, is finishing his last semester of an engineering degree and was referred for a liver workup after a routine pre-graduation physical found elevated transaminases his student health clinic couldn't explain — the ordinary route into a Wilson diagnosis, since the hepatic presentation typically declares itself a decade or more before the neurologic one and often, as here, on a lab drawn for something else entirely. He is also, at 22, at the age where the therapeutic decision made now will govern forty years of copper handling rather than four. Further workup found low ceruloplasmin and elevated 24-hour urinary copper; slit-lamp exam found no Kayser-Fleischer rings, and genetic testing confirmed two pathogenic ATP7B variants. He has no tremor, no dysarthria, no gait abnormality, and no psychiatric symptoms on a full neurologic exam, and the absence of Kayser-Fleischer rings fits that picture rather than contradicting it — the rings track neurologic involvement closely enough that their absence in a patient with confirmed disease is itself evidence his brain is not yet involved. His liver biopsy shows moderate fibrosis without cirrhosis, which places him in the window where copper removal can still change the trajectory of the organ actually at risk. Read together, his findings describe a patient with real, active hepatic copper toxicity and nothing on the neurologic side to weigh against the faster, more potent option — which is precisely the configuration that makes the standard caution about chelation in Wilson disease not apply to him.
For Simon, I'd start a chelator — trientine specifically. He has real, ongoing hepatic copper toxicity and no neurologic disease to weigh against a faster, more potent copper-mobilizing agent. There's no reason to accept zinc's slower onset when the organ actually at risk right now is his liver alone.
I'd agree on the chelator class, and specifically on trientine over penicillamine even here, where the neurologic-worsening concern doesn't directly apply. Penicillamine's early hypersensitivity reaction rate is meaningfully higher, and Weiss's multicenter comparison of chelator and zinc regimens found no efficacy penalty for trientine in hepatic disease — so there's no reason to accept that risk here.
Trientine started, with 24-hour urinary copper and liver function monitored at the standard interval to guide titration.
Renata V., a 34-year-old woman, teaches middle school science and first came to attention when her students noticed her handwriting had become difficult to read and her speech occasionally slurred during class, prompting a colleague to suggest she see a doctor. That her presenting complaint arrived through other people's observation rather than her own is characteristic of neurologic Wilson disease, where the deficits are often more obvious from outside than in, and it matters practically: the tremor and dysarthria she has been living with are almost certainly older than the day they were first named. Workup found low ceruloplasmin, elevated 24-hour urinary copper, and Kayser-Fleischer rings on slit-lamp exam; genetic testing confirmed two pathogenic ATP7B variants, the same underlying diagnosis as Simon's. Her neurologic exam shows a mild resting tremor, mild dysarthria, and subtle gait unsteadiness, and her Kayser-Fleischer rings — present where Simon's were absent — corroborate that the deposition has reached her brain rather than resting in her liver alone. Her liver enzymes are only mildly elevated, without significant fibrosis on noninvasive testing, so the organ Simon is being treated to protect is, in her case, the one least at risk. That inversion is the whole difficulty: the drugs that mobilize copper fastest are the ones associated with paradoxical early neurologic worsening, and she is the patient with neurologic findings to worsen. Identical genotype, identical copper studies, opposite therapeutic logic.
For Renata, I'd start zinc, not a chelator. Chelator-induced paradoxical neurologic worsening is a real, described risk, concentrated early in treatment, and it's specifically a risk to the system already showing damage in her case. Zinc works more slowly, but it doesn't carry that same early-worsening signal, and slower control of a system already compromised is a more defensible tradeoff than fast control that risks making it acutely worse.
I understand the concern, and I wouldn't push a chelator here the way I would in a purely hepatic case. But her liver enzymes are elevated too, even if mildly, and zinc's slower copper-mobilizing effect means slower control on that front as well. I'd want us to be explicit that we're accepting slower hepatic control as a tradeoff for neurologic safety, not treating zinc as equally effective on both fronts.
'Equally effective on both fronts' was never the claim — the claim is that the neurologic risk is the one that should set the choice here, given how mild her hepatic findings actually are next to her active neurologic disease.
Zinc started, with a plan to reassess both neurologic exam findings and 24-hour urinary copper at three months.
The hepatologist's point about accepting slower hepatic control was documented explicitly as a known tradeoff rather than an oversight, so a future team revisiting her case understands the choice was deliberate.